William Sheppard, MD
Otolaryngology · Newark, DENPI 1427092501
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Novartis at 30.3% of the total. Reporting peaked in 2022 at $270 and has fallen 68.7% since, to $84 in 2025. That places this record below the midpoint for otolaryngology clinicians in DE, where the typical reported total is $1,648.
Across 36 payments — averaging $21.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$235
- Genentech USA, Inc.$113
- Intersect ENT, Inc.$92
- Takeda Pharmaceuticals U.S.A., Inc.$57
- CSL Behring$50
- Incyte Corporation$28
- plus $203 from 11 others
What the payments were for
- Food & beverage$778100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $235 |
| Genentech USA, Inc. | 5 | $113 |
| Intersect ENT, Inc. | 1 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $57 |
| CSL Behring | 2 | $50 |
| Incyte Corporation | 1 | $28 |
| AstraZeneca | 2 | $27 |
| Biocryst US Sales Co., LLC | 1 | $21 |
| Bio Products Laboratory USA, Inc. | 1 | $21 |
| GSK | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Pharming Healthcare, Inc. | 1 | $18 |
| Merck | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Stryker | 1 | $14 |
| Optinose US, Inc. | 1 | $12 |
How this compares
$778 in reported general payments places this provider in the 30th percentile of 27 otolaryngology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 169 | $6,270 |
| Ipratropium Bromide | 87 | $4,048 |
| Nortriptyline Hcl | 187 | $3,365 |
| Mometasone Furoate | 89 | $2,726 |
| Ofloxacin | 64 | $2,722 |
| Acetazolamide | 32 | $1,875 |
| Pantoprazole Sodium | 93 | $1,356 |
| Fluticasone Propionate | 60 | $1,337 |
| Mupirocin | 49 | $890 |
| Montelukast Sodium | 46 | $816 |
| Fluocinolone Acetonide Oil | 14 | $644 |
| Topiramate | 57 | $534 |
| Omeprazole | 34 | $513 |
| Gabapentin | 36 | $454 |
| Famotidine | 28 | $443 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Newark
- David LaffertyNewark$9K
- Jagdeep HundalNewark$6K
- Todd SpockNewark$4K
- Robert WardlowNewark$3K
- Gregg GoldsteinNewark$2K
- Julian AminNewark$1K
- John McIntireNewark$1K
- Avishai Stahl AltmanNewark$111
- Jonathan RomakNewark$93
- Robert WittNewark$54
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.